ScholarIQanswers from OpenAlex
Parker Institute for Cancer Immunotherapy
InstitutionResearch output, impact & collaborations
Parker Institute for Cancer Immunotherapy is a institution indexed in ScholarIQ from OpenAlex.
What is known about Parker Institute for Cancer Immunotherapy?
ScholarIQrecord summary
Parker Institute for Cancer Immunotherapy is a research organisation in San Francisco, US. OpenAlex records 2,373 works and 562,976 citations for it. 595 researchers list it as their most recent affiliation.
How many works does Parker Institute for Cancer Immunotherapy have?
ScholarIQindexed works
Parker Institute for Cancer Immunotherapy has 2,373 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Parker Institute for Cancer Immunotherapy have?
ScholarIQcitation count
Parker Institute for Cancer Immunotherapy has 562,976 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Parker Institute for Cancer Immunotherapy?
ScholarIQresearcher count
Parker Institute for Cancer Immunotherapy has 595 researchers in the ScholarIQ index.
What is the average h-index at Parker Institute for Cancer Immunotherapy?
ScholarIQavg h-index
Parker Institute for Cancer Immunotherapy has an average h-index of 82.6 in OpenAlex.
What is the ROR of Parker Institute for Cancer Immunotherapy?
ScholarIQror
The ROR for Parker Institute for Cancer Immunotherapy is on the source record.
What is the OpenAlex record for Parker Institute for Cancer Immunotherapy?
ScholarIQopenalex
The OpenAlex for Parker Institute for Cancer Immunotherapy is on the source record.
Who are the most-cited researchers behind Parker Institute for Cancer Immunotherapy?
ScholarIQtop researchers by citations
What are the most-cited papers on Parker Institute for Cancer Immunotherapy?
ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W Lee, James N. Kochenderfer, Maryalice Stetler‐Stevenson, Yongzhi Cui, Cindy Delbrook, Steven A. Feldman, Terry J. Fry, Rimas J. Orentas, Marianna Sabatino, Nirali N. Shah, Seth M. Steinberg, D. Stroncek, Nick Tschernia, Constance M. Yuan, Hua Zhang, Ling Zhang, Steven A. Rosenberg, Alan S. Wayne, Crystal L. Mackall
Who collaborates most closely around Parker Institute for Cancer Immunotherapy?
ScholarIQco-authorship network
United States
100%
MOST FREQUENT PARTNER INSTITUTIONS
How much of the research on Parker Institute for Cancer Immunotherapy is open access?
ScholarIQopen access share
75%OPEN ACCESS